Ahmed Alnughmush, Suheil Albert Atallah-Yunes, Tamer Hellou, Thomas M. Habermann, Yucai Wang, Javier Munoz, Madiha Iqbal, Rebecca L. King, William G. Breen, Jose C. Villasboas, Thomas E. Witzig, Stephen M. Ansell, Grzegorz S. Nowakowski
<p>Extranodal marginal zone lymphoma (EMZL) of mucosa-associated lymphoid tissue (MALT) constitutes approximately 70% of all marginal zone lymphoma (MZL) cases, with the gastric subtype representing the most prevalent anatomical site of origin [<span>1</span>]. Although MALT lymphomas have been described across a broad spectrum of extranodal sites, data specifically addressing primary breast involvement remains limited, largely derived from small case series and population-based analyses, such as those using the SEER database [<span>2-5</span>]. This knowledge gap is particularly relevant in light of epidemiologic trends indicating a decline in the incidence of gastric MALT lymphoma, accompanied by a rising incidence of non-gastric subtypes, including primary breast MALT lymphoma [<span>6, 7</span>].</p><p>Primary breast lymphoma accounts for less than 1% of all non-Hodgkin lymphomas and approximately 3% of extranodal cases. Among these, diffuse large B-cell lymphoma represents the predominant histologic subtype, whereas primary breast MALT lymphoma comprises an estimated 20%–25% of cases [<span>7-9</span>].</p><p>In light of these observations, we sought to provide a comprehensive evaluation of this rare entity, detailing its clinical characteristics, treatment patterns, and outcomes. To our knowledge, this represents the largest single-institution cohort reported to date, with the goal of improving the delineation of clinical features and guiding contemporary management practices.</p><p>Following institutional review board approval, we conducted a retrospective analysis of 38 patients diagnosed with primary breast MALT lymphoma at Mayo Clinic between 1993 and 2024, identified through Epic electronic medical records. Patients were excluded if they had a prior history of MALT lymphoma or if breast involvement occurred as part of disseminated systemic disease. Clinical, pathological, and treatment-related data were abstracted through manual review of the electronic medical records. Statistical analyses were performed using JMP Pro version 17.0.0 (SAS Institute, Cary, NC, USA), with two-sided <i>p</i> values < 0.05 considered statistically significant.</p><p>Event-free survival (EFS) was defined as the interval from diagnosis to disease progression, initiation of subsequent unplanned therapy, or death from any cause and was censored at the date of last follow-up. Overall survival (OS) was defined as the time from diagnosis to death from any cause, with censoring at last known follow-up.</p><p>A total of 38 patients were identified with unilateral or bilateral primary breast MALT lymphoma. The median age at diagnosis was 65.5 years (IQR, 61–74), and the vast majority were female (97.4%). Patient and disease characteristics are summarized in Table 1. Most cases (<i>n</i> = 30, 78.9%) were diagnosed incidentally, with 29 (96.7%) detected on routine screening mammography and one (3.3%) identified via chest CT performed for surveillance of a prior ma
{"title":"Primary Breast MALT Lymphoma: Clinical Features and Outcomes From a Single-Institution Experience at Mayo Clinic","authors":"Ahmed Alnughmush, Suheil Albert Atallah-Yunes, Tamer Hellou, Thomas M. Habermann, Yucai Wang, Javier Munoz, Madiha Iqbal, Rebecca L. King, William G. Breen, Jose C. Villasboas, Thomas E. Witzig, Stephen M. Ansell, Grzegorz S. Nowakowski","doi":"10.1002/ajh.70178","DOIUrl":"10.1002/ajh.70178","url":null,"abstract":"<p>Extranodal marginal zone lymphoma (EMZL) of mucosa-associated lymphoid tissue (MALT) constitutes approximately 70% of all marginal zone lymphoma (MZL) cases, with the gastric subtype representing the most prevalent anatomical site of origin [<span>1</span>]. Although MALT lymphomas have been described across a broad spectrum of extranodal sites, data specifically addressing primary breast involvement remains limited, largely derived from small case series and population-based analyses, such as those using the SEER database [<span>2-5</span>]. This knowledge gap is particularly relevant in light of epidemiologic trends indicating a decline in the incidence of gastric MALT lymphoma, accompanied by a rising incidence of non-gastric subtypes, including primary breast MALT lymphoma [<span>6, 7</span>].</p><p>Primary breast lymphoma accounts for less than 1% of all non-Hodgkin lymphomas and approximately 3% of extranodal cases. Among these, diffuse large B-cell lymphoma represents the predominant histologic subtype, whereas primary breast MALT lymphoma comprises an estimated 20%–25% of cases [<span>7-9</span>].</p><p>In light of these observations, we sought to provide a comprehensive evaluation of this rare entity, detailing its clinical characteristics, treatment patterns, and outcomes. To our knowledge, this represents the largest single-institution cohort reported to date, with the goal of improving the delineation of clinical features and guiding contemporary management practices.</p><p>Following institutional review board approval, we conducted a retrospective analysis of 38 patients diagnosed with primary breast MALT lymphoma at Mayo Clinic between 1993 and 2024, identified through Epic electronic medical records. Patients were excluded if they had a prior history of MALT lymphoma or if breast involvement occurred as part of disseminated systemic disease. Clinical, pathological, and treatment-related data were abstracted through manual review of the electronic medical records. Statistical analyses were performed using JMP Pro version 17.0.0 (SAS Institute, Cary, NC, USA), with two-sided <i>p</i> values < 0.05 considered statistically significant.</p><p>Event-free survival (EFS) was defined as the interval from diagnosis to disease progression, initiation of subsequent unplanned therapy, or death from any cause and was censored at the date of last follow-up. Overall survival (OS) was defined as the time from diagnosis to death from any cause, with censoring at last known follow-up.</p><p>A total of 38 patients were identified with unilateral or bilateral primary breast MALT lymphoma. The median age at diagnosis was 65.5 years (IQR, 61–74), and the vast majority were female (97.4%). Patient and disease characteristics are summarized in Table 1. Most cases (<i>n</i> = 30, 78.9%) were diagnosed incidentally, with 29 (96.7%) detected on routine screening mammography and one (3.3%) identified via chest CT performed for surveillance of a prior ma","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 3","pages":"639-643"},"PeriodicalIF":9.9,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70178","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145852894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to “Budesonide, Added to PTCy ‐Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation”","authors":"","doi":"10.1002/ajh.70179","DOIUrl":"https://doi.org/10.1002/ajh.70179","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"12 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145844740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}